CJC-1295 / Ipamorelin
GHRH Analog + GH Secretagogue Research Blend
Also referenced as: CJC-1295 (no DAC) + Ipamorelin Blend · Modified GRF 1-29 + Ipamorelin · GHRH Analog + GH Secretagogue Stack
≥99% Purity Guaranteed
Full Panel COA
UPS 2-Day Air Shipping
Shipment InsuredShipment Insurance Included
Lab Results
| Test | Result | Status |
|---|---|---|
| Purity | – | Pending |
| Quantitation (Avg) | – | Pending |
| Heavy Metals (ICP-MS) | – | Pending |
| Endotoxin (USP <85>) | – | Pending |
| Sterility (PCR) | – | Pending |
| Multi Vial Tested | – | Pending |
Made in cGMP- and ISO-certified facilities vetted by our established North American supply partner. Virtus tracks the factory batch number on every lot and catalogues it against independent lab testing, with a final Certificate of Analysis from ILS Laboratories. We pay more to source this way because we hold the highest standard for the product and for you.
Curated research on CJC-1295 / Ipamorelin
Jette L (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology.
PMID: 15817669 →Soule S (1994). Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men J Clin Endocrinol Metab.
PMID: 7962295 →Raun K (1998). Ipamorelin, the first selective growth hormone secretagogue Eur J Endocrinol.
PMID: 9849822 →Andersen NB (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats Growth Horm IGF Res.
PMID: 11735244 →
About CJC-1295 / Ipamorelin
A two-peptide research blend combining CJC-1295 without DAC (Modified GRF 1-29, 5mg) and Ipamorelin (5mg) in a single 10mg lyophilized vial. The blend pairs a growth-hormone-releasing hormone (GHRH) analog with a selective growth-hormone secretagogue, two complementary pathways studied in preclinical research on somatotroph signaling and growth-hormone release.
CJC-1295 (no DAC) is a tetra-substituted analog of GRF(1-29) that engages the GHRH receptor on anterior-pituitary cells, while Ipamorelin is a pentapeptide agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). The blend combines these two research compounds into a single formulation for laboratory studies of the GHRH and ghrelin-receptor pathways at the cellular level.
Also Referenced As
CJC-1295 (no DAC) + Ipamorelin Blend · Modified GRF 1-29 + Ipamorelin · GHRH Analog + GH Secretagogue Stack
Specifications
- Scientific Name
- CJC-1295 (Modified GRF 1-29) + Ipamorelin: Two-Peptide Research Blend
- CAS Number
- 446036-97-1 / 170851-70-4
- Molecular Formula
- CJC-1295 C₁₅₂H₂₅₂N₄₄O₄₂ · Ipamorelin C₃₈H₄₉N₉O₅
- Molecular Weight
- Blend: CJC-1295 (no DAC) 3,367.9 g/mol · Ipamorelin 711.9 g/mol
- Physical Form
- Lyophilized powder
- Purity
- Coming Soon
- Batch Number
- TBD
- Storage
- −20°C, protected from light, avoid repeated freeze-thaw cycles
Storage & Handling
Lyophilized peptides remain stable for 12–24 months when stored properly. Follow standard laboratory protocols for handling.
Storage
Store lyophilized peptide at −20°C in a standard laboratory freezer, protected from light, moisture, and heat. Avoid repeated freeze-thaw cycles.
Shelf Life
Lyophilized form remains stable for 12–24 months at −20°C in the original sealed vial. Always reference the batch-specific COA for verified shelf-life data.
Mechanism & Research Background
This blend supplies 10mg total per vial: CJC-1295 without DAC (Modified GRF 1-29, 5mg) and Ipamorelin (5mg). Each component has been independently characterized in research literature across two complementary growth-hormone-axis pathways: the GHRH receptor and the ghrelin / growth-hormone-secretagogue receptor.
CJC-1295 (no DAC) is a 29-amino-acid analog of human GRF(1-29), the shortest fully active fragment of native GHRH. It carries four substitutions, notably D-Ala at position 2, studied in vitro for increased resistance to dipeptidyl-peptidase-IV (DPP-IV) cleavage. In cultured somatotroph models the GHRH receptor (a class-B GPCR) couples to Gs / adenylyl cyclase, raising cAMP and activating PKA / CREB signaling associated with growth-hormone gene expression. Unlike the DAC-conjugated version, the no-DAC form lacks the albumin-binding linker and is studied as a short-acting GRF analog.
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide of the growth-hormone-secretagogue class that acts in vitro as a selective agonist of GHS-R1a, the receptor for endogenous ghrelin. In characterization work it was described as the first selective secretagogue, stimulating growth-hormone release in pituitary-cell and animal models without significantly elevating ACTH, cortisol, or prolactin above baseline. The blend combines these two research compounds in a single formulation; products supplied by Virtus Peptides are intended exclusively for in-vitro laboratory research and are not for human or animal use.
